Vitamin C Trial Shows Reduced Deaths in Blood Disorder Patients
A phase 2 trial involving 109 participants in Denmark and the United States showed that daily vitamin C supplementation was associated with fewer deaths and complications in patients with precancerous or low-risk blood cancers. The study revealed a reduction in anemia, pneumonia, and internal bleeding, although gastrointestinal issues were noted. Further research is needed to confirm these findings in a larger trial.
A recent phase 2 clinical trial has shown that daily vitamin C supplementation may lead to fewer deaths and complications in patients with precancerous or low-risk blood cancers. Conducted with 109 participants across Denmark and the United States, the EVITA trial examined the effects of vitamin C on individuals at risk of developing blood cancers. The results, published in the journal CANCER, revealed that while the supplement did not slow the growth of abnormal cells, it was linked to favorable changes in inflammation and a significant reduction in cases of anemia, pneumonia, and internal bleeding. Notably, fewer participants in the vitamin C group died during the follow-up period compared to those receiving a placebo, indicating a potential survival benefit from the supplement.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Liam covers climate solutions and the people helping the planet heal.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
